Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 20/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22420093 | 0.92 | FGFR4 (0.74) | FGFR4FGFR2 | |
| SCHEMBL19363701 | 0.87 | FGFR4 (0.74) | FGFR4FGFR2 | |
| SCHEMBL19363628 | 0.87 | FGFR4 (0.69) | FGFR4FGFR2 | |
| SCHEMBL19363626 | 0.86 | FGFR4 (0.73) | FGFR4FGFR2 | |
| SCHEMBL19363575 | 0.85 | FGFR4 (0.72) | FGFR4FGFR2 | |
| SCHEMBL16071387 | 0.85 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL18897273 | 0.82 | FGFR4 (0.73) | FGFR4 | |
| SCHEMBL19363576 | 0.82 | FGFR4 (0.69) | FGFR4FGFR2 | |
| SCHEMBL19363630 | 0.81 | FGFR4 (0.67) | FGFR4FGFR2 | |
| SCHEMBL19363703 | 0.79 | FGFR4 (0.64) | FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.